| Name | Title | Contact Details |
|---|
Bridgewater Bank is a full-service financial institution based in St. Louis Park, Minnesota, founded in 2005. As a subsidiary of Bridgewater Bancshares, Inc., it is one of the largest locally-led banks in the state, with total assets of approximately $5.14 billion and nine branches across the Twin Cities area. The bank focuses on providing personalized, relationship-driven banking experiences for entrepreneurs, business professionals, and individuals. Its offerings include commercial banking services such as real estate lending, construction financing, and treasury management, as well as personal banking products like checking and savings accounts, loans, and certificates of deposit. Bridgewater Bank is committed to supporting its clients with tailored financial solutions and a strong emphasis on community connection.
2023 Earthshot Prize Finalist on a mission to protect the planet from the cost of clothing. At Circ, weve created a technology system that returns clothes to the raw materials from which they were made. Again and again. Brand partners like Patagonia, Marubeni, and Fashion For Good are joining us in our goal of turning wasteful fashion lines into renewable fashion circles. By 2030, we expect to have recycled 10 billion garments, represent 10% of the global apparel market, and to have saved more than 100 million trees. As our ecology and economy grow evermore entwined, it is clear to us that the world already has all the clothing it needs to create all the clothing it will ever need. Join us in threading together the future of circular fashion and eliminating our collective fashion footprint.
MedVet is the leading veterinarian owned and led network of specialty and emergency hospitals dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 35 years, MedVets empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. Our caregivers are deeply committed to MedVets mission of Leading Specialty Healthcare for Pets and our driven by our core values of Teamwork, Leadership, and Compassion. Visit www.medvet.com for further information and to view employment opportunities at MedVet. MedVet is an Equal Opportunity Employer.
We are brewing up something incredible here at HTeaO. In January of 2018 we launched our franchise prototype store in Midland, TX. Our desire is to provide ultra-premium Tea, Water and related products that give people safe and healthy food choices in a fun and clean environment. We are committed to providing the absolute best quality iced tea money can buy in a retail environment. With the incredible support of our customers we are entering into a season where we teach, train and mentor franchisees in growing their own successful business. Would you like to join us?
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.